# First Turn Management, LLC 13F Q2 2026: $935 million

First Turn Management, LLC reported $935 million in 13F securities across 31 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Revolution Medicines Inc at $77.8 million, 8.3% of the reported value. Since Q1 2026 it opened 6 new positions and exited 8.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $934,715,611
- Positions: 31
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1993440
- Form 13F file number: 028-23631
- CRD number: 327421
- Business address: 1155 Camino Del Mar, Suite 734, Del Mar, CA 92014
- SEC filing: [0001993440-26-000004](https://www.sec.gov/Archives/edgar/data/1993440/000199344026000004/0001993440-26-000004-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/first-turn-management-llc-327421)

## Top 25 holdings by value

The largest of 31 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 415,307 | $77.8 million | -53,069 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 489,889 | $65.3 million | +24,020 |
| [Axsome Therapeutics Inc.](https://specstream.ai/data/institutional-holders/axsome-therapeutics-inc-05464t104) | COM | 218,415 | $53.5 million | +29,643 |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 954,360 | $48.4 million | +330,521 |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 633,364 | $47.2 million | -62,354 |
| [Roivant Sciences LTD](https://specstream.ai/data/institutional-holders/roivant-sciences-ltd-g76279101) | SHS | 1,331,066 | $47.1 million | +140,948 |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 84,932 | $46 million | -19,794 |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 527,412 | $44.9 million | +243,712 |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 600,200 | $36.2 million | -186,644 |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102k100) | COM | 329,101 | $34.4 million | +118,523 |
| [Viridian Therapeutics Inc](https://specstream.ai/data/institutional-holders/viridian-therapeutics-inc-92790c104) | COM | 1,670,000 | $30.7 million | +758,663 |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 263,851 | $28.1 million | +15,376 |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 608,925 | $28 million | -6,564 |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 104,877 | $28 million | New |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 83,528 | $28 million | +41,087 |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 285,771 | $27.9 million | +64,850 |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 443,836 | $25.8 million | New |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 218,051 | $25.5 million | -182,413 |
| [Palvella Therapeutics Inc Ne](https://specstream.ai/data/institutional-holders/palvella-therapeutics-inc-ne-697947109) | COM | 156,450 | $23.9 million | +8,357 |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 602,281 | $23.3 million | -345,058 |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 1,221,721 | $22.4 million | +354,082 |
| [Oric Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/oric-pharmaceuticals-inc-68622p109) | COM | 2,017,284 | $21.8 million | No change |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 582,497 | $19.7 million | +24,161 |
| [Apogee Therapeutics Inc](https://specstream.ai/data/institutional-holders/apogee-therapeutics-inc-03770n101) | COM | 138,822 | $18.4 million | -374,948 |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 154,018 | $17.1 million | New |

## New positions in Q2 2026

6 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 104,877 | $28 million |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 443,836 | $25.8 million |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 154,018 | $17.1 million |
| [Inhibrx Biosciences Inc](https://specstream.ai/data/institutional-holders/inhibrx-biosciences-inc-45720n103) | COM | 164,783 | $15.6 million |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 155,343 | $14.8 million |
| [Sionna Therapeutics Inc](https://specstream.ai/data/institutional-holders/sionna-therapeutics-inc-829401108) | COM | 110,493 | $4.9 million |

## Positions exited in Q2 2026

8 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ideaya Biosciences Inc](https://specstream.ai/data/institutional-holders/ideaya-biosciences-inc-45166a102) | COM | 873,838 | $29.1 million |
| Ascendis Pharma A/S | SPONSORED ADR | 76,300 | $17.5 million |
| [Fulcrum Therapeutics Inc](https://specstream.ai/data/institutional-holders/fulcrum-therapeutics-inc-359616109) | COM | 2,256,109 | $17.3 million |
| Terns Pharmaceuticals Inc | COM | 326,694 | $17.2 million |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 422,023 | $17 million |
| [Natera Inc](https://specstream.ai/data/institutional-holders/natera-inc-632307104) | COM | 81,077 | $16.2 million |
| [Olema Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/olema-pharmaceuticals-inc-68062p106) | COM | 768,662 | $11.5 million |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 315,563 | $5.9 million |

## Also on SpecStream

- [First Turn Management, LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1993440/000199344026000004/0001993440-26-000004-index.htm)
- [First Turn Management, LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/first-turn-management-llc-327421)
- [Largest 13F filers in California](https://specstream.ai/data/institutional-holdings/state/california)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in California

- [Equipment rental companies in California, United States](https://specstream.ai/data/businesses/equipment-rental-companies/california-united-states)
- [Driving schools in California, United States](https://specstream.ai/data/businesses/driving-schools/california-united-states)
- [Credit and debt counseling services in California, United States](https://specstream.ai/data/businesses/credit-and-debt-counseling-services/california-united-states)
- [Clothing companies in California, United States](https://specstream.ai/data/businesses/clothing-companies/california-united-states)
- [Cancer treatment centers in California, United States](https://specstream.ai/data/businesses/cancer-treatment-centers/california-united-states)
- [Bistros in California, United States](https://specstream.ai/data/businesses/bistros/california-united-states)
